Cargando…
Abrocitinib: First Approval
Abrocitinib (Cibinqo(®)) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In September 2021, abrocitinib was approved in the UK and Japan for the treatment of moderate-to-severe AD in adults and ado...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917037/ https://www.ncbi.nlm.nih.gov/pubmed/34807428 http://dx.doi.org/10.1007/s40265-021-01638-3 |